Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in…
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application…
BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial…
REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of…
SARASOTA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for…
NEW YORK and LONDON and BERLIN and TOKYO, Feb. 4, 2025 /PRNewswire/ -- Sony Group Corporation (Sony) and Nature are proud…
ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced…
Nearly three million members of the largest health insurance plan in Massachusetts are now eligible for reimbursement when prescribed with…
Multi-million-pound funding to drive development of next-gen neural implant, neuromodulation and neurosensing therapeutics for clinical use LONDON, Jan. 31, 2025…
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era…
